What's Actually in a Dog's Calming Chews
Last reviewed · Citation policy
L-theanine, chamomile, valerian, melatonin, CBD, probiotics — an ingredient-by-ingredient breakdown of what has evidence, what doesn't, and what "proprietary blend" is hiding.
Published
2023
Updated
Apr 10, 2026
References
5 selected
Ingredient-by-ingredient evidence review
Commercial canine calming chews span several pharmacological categories with markedly different evidence profiles. Understanding the evidence base for each ingredient class is necessary to evaluate product claims and the utility of specific formulations. For how these ingredient profiles translate to format decisions, see the guide on calming chews vs. diffusers.
Alpha-casozepine
Best-studied peptide anxiolytic in canine-specific trials.
Alpha-casozepine is a decapeptide derived from bovine αs1-casein (milk protein). Its mechanism of action — GABA-A receptor benzodiazepine binding site affinity — has been confirmed in rodent models (Benoit et al., 2022; PMCID: PMC9182760), providing mechanistic plausibility for anxiolytic effects. The most controlled dog evidence for a formulation that includes alpha-casozepine comes from Flint et al. (2025; PMCID: PMC12339541): a CBD 2 mg/kg, L-tryptophan, and alpha-casozepine treat significantly attenuated cortisol during car-travel stress (p=0.016), while the CBD monotherapy arms did not. The multi-ingredient design prevents attribution to alpha-casozepine specifically; alpha-casozepine is the constituent most frequently associated with anxiolytic claims in the proprietary canine supplement literature, but clean single-ingredient controlled trial evidence in dogs is not available.
L-theanine
Glutamate analog with GABAergic activity; moderate canine-specific evidence.
L-theanine is a non-protein amino acid found in tea (Camellia sinensis) that modulates glutamatergic and GABAergic neurotransmission. Canine-specific studies have produced directionally positive but modest results. Riemer (2023; PMCID: PMC10705068) includes L-theanine in the practitioner review of anxiolytic interventions for noise-related fear, noting that evidence for efficacy exists but remains limited in scale. Most L-theanine canine studies have used proprietary branded formulations (Zylkène, Anxitane) that combine the compound with other ingredients, limiting constituent-level attribution.
CBD (cannabidiol)
Primarily studied in pain models; anxiolytic evidence weak for monotherapy.
CBD as a standalone anxiolytic in dogs lacks demonstrated efficacy in the best available controlled trial. Flint et al. (2025; PMCID: PMC12339541) evaluated CBD at 2 mg/kg and 4 mg/kg versus placebo in a blinded 4-arm crossover (n=54), finding neither dose significantly attenuated salivary cortisol during car-travel stress. The only significant arm paired CBD 2 mg/kg with L-tryptophan and alpha-casozepine (p=0.016). Di Salvo et al. (2023; PMCID: PMC10347378) noted that most canine CBD efficacy data derives from osteoarthritis models, not behavioral applications.
Melatonin
Widely prescribed empirically; lacks controlled canine anxiolysis trial evidence.
Exogenous melatonin is commonly included in situational anxiety protocols — particularly for noise phobia — and is prescribed by veterinarians based on empirical clinical experience. No controlled canine anxiolysis trials meeting standard evidence criteria were identified in this review. Clinical use is based on extrapolation from mammalian circadian physiology and empirical veterinary practice rather than trial-level evidence in dogs.
Botanicals: valerian, chamomile, passionflower
In vitro and rodent evidence only; no well-controlled standalone canine trials.
These phytochemical extracts appear across numerous commercial formulations, with marketing references to GABAergic or serotonergic mechanisms. While in vitro and rodent research documents plausible mechanisms, standalone canine behavioral evidence for these botanicals remains absent. Passionflower appeared in the DìRelax formulation (Scandurra et al., 2022; PMCID: PMC8868118) as one of six active ingredients, but the multi-ingredient design does not permit attribution.
Probiotics
Mechanistically plausible via gut-brain axis; canine behavioral evidence preliminary.
Sacoor et al. (2024; PMCID: PMC10827376) synthesized the gut-brain axis evidence for canine anxiety, covering vagal afferent signaling, microbial metabolite pathways, and HPA axis modulation. While the mechanistic framework is well-developed, controlled interventional evidence specifically in dogs with characterized anxiety disorders is limited. Probiotic interventions in calming chews represent a promising but not yet clinically established ingredient category.
Key takeaway
The evidence hierarchy across ingredients: alpha-casozepine and L-theanine have the most canine-specific controlled evidence (though primarily in multi-ingredient designs). CBD monotherapy lacks demonstrated anxiolytic efficacy in the best available trial. Melatonin and botanicals lack controlled canine behavioral trial evidence. Probiotics are mechanistically plausible but unvalidated.
The proprietary blend problem
Many commercial calming chews list a "proprietary blend" on the label — a combined total weight for a mixture of ingredients without disclosing the individual ingredient quantities. This labeling format is permitted under US dietary supplement regulations and is common in both human and pet supplement markets.
The clinical problem with proprietary blends is that ingredient dose matters. The published studies on alpha-casozepine, L-theanine, and CBD used specific dose ranges. A product listing alpha-casozepine as the first ingredient in a proprietary blend might contain a token quantity — enough to appear on the label but well below the doses used in published research. Without per-ingredient dosing transparency, a product cannot be compared to published evidence, regardless of how many studied ingredients it lists.
Key takeaway
Proprietary blend labeling prevents dose verification against published evidence. A product can list an ingredient with an evidence basis while containing an undisclosed, potentially sub-therapeutic amount. Per-ingredient milligram disclosure is required for meaningful label interpretation.
What the NASC seal addresses
The National Animal Supplement Council (NASC) quality seal program requires participating manufacturers to follow Good Manufacturing Practices (GMP), maintain accurate labeling and ingredient records, and participate in an adverse event reporting system. These are manufacturing and safety standards.
The NASC seal does not evaluate, verify, or endorse clinical efficacy. A product with the NASC seal may contain ingredients with no controlled canine trial evidence. Conversely, a product without the seal may contain well-studied ingredients at clinically meaningful doses. The seal addresses the quality and safety of the manufacturing process — not the therapeutic merit of the formulation.
Key takeaway
The NASC seal is a manufacturing quality standard, not a clinical efficacy endorsement. Presence or absence of the seal does not indicate whether a product's ingredients have evidence of therapeutic benefit in dogs.
Dose transparency in the literature vs. on labels
Published studies that find positive signals for calming ingredients typically report specific doses used in the trial. Flint et al. (2025; PMCID: PMC12339541) used CBD at exactly 2 mg/kg and 4 mg/kg; Scandurra et al. (2022; PMCID: PMC8868118) used a specific multi-ingredient formulation at a defined total dose. These dose specifications are the only basis for comparing a commercial product to the evidence.
Products that list per-ingredient milligram amounts on the label allow direct comparison to published dose ranges. Products that use proprietary blend labeling do not. From an evidence-based perspective, per-ingredient milligram transparency is a necessary (though not sufficient) condition for evaluating whether a product delivers doses that might match those in published studies.
A secondary consideration is the dose relative to body weight: the same fixed milligram dose produces very different exposure in a 5 kg dog than in a 40 kg dog. Fixed-dose formulations that do not account for body weight produce variable mg/kg exposures across dogs of different sizes — a pharmacokinetically meaningful variability.
Key takeaway
Per-ingredient milligram disclosure is the minimum transparency required to compare a commercial product to published evidence. Fixed-dose products applied across a wide range of body weights produce variable mg/kg exposures — a pharmacokinetically relevant inconsistency.
Evidence gaps and limitations
Most published calming chew studies evaluate proprietary multi-ingredient formulations, making it impossible to attribute observed effects to individual ingredients even when the trial methodology is sound. Single-ingredient controlled studies in dogs are rare for most calming treat constituents.
Study populations are typically small (n=21 to n=54 in the most cited trials) and have not been stratified by anxiety phenotype — dogs with noise phobia, separation-related distress, and generalized anxiety have been pooled rather than studied separately, despite different pharmacological rationales for ingredient selection across anxiety types.
Outcome measures vary substantially across studies: C-BARQ subscales, cognitive task performance, salivary cortisol, heart rate variability, and owner global impression are not interchangeable or directly comparable. This heterogeneity limits the ability to synthesize across studies.
Key takeaway
The calming chew ingredient literature is constrained by multi-ingredient designs that prevent attribution, small samples, lack of anxiety-phenotype stratification, and heterogeneous outcome measures. Translating population-level study findings to individual product decisions requires substantial inferential steps not supported by current evidence.
How this guide connects to the Pawsd knowledge base
The ingredient map ties calming-chew constituents to evidence tiers and labeling constraints. Scout uses it to distinguish canine trial data from mechanistic plausibility, then checks whether labels provide per-ingredient dosing or certification details that make comparison to published research possible. Ingredient tiers are revisited when new canine trials or labeling standards change that comparison.
Frequently asked questions
Which calming chew ingredient has the strongest canine-specific evidence?
Alpha-casozepine has the most consistent positive signals in canine-specific controlled studies among common calming chew ingredients. Its mechanism of action (GABA-A benzodiazepine site affinity) has been confirmed in rodent models (Benoit et al., 2022; PMCID: PMC9182760). A 30-day blinded RCT using a multi-ingredient formulation containing alpha-casozepine found cognitive task performance improvements and C-BARQ subscale changes in 21 dogs (Scandurra et al., 2022; PMCID: PMC8868118). The multi-ingredient design prevents clean attribution, but alpha-casozepine is the constituent with the strongest evidence profile across available studies.
What does "proprietary blend" on a calming chew label mean?
A proprietary blend lists the combined total weight of a mixture of ingredients without disclosing how much of each ingredient is included. This means the label cannot be compared to published study doses — a product listing alpha-casozepine in a proprietary blend may contain a token quantity well below the doses used in research. Per-ingredient milligram disclosure is required to evaluate whether a product's formulation is meaningfully comparable to evidence-based dose ranges.
Does the NASC seal indicate that a calming chew has demonstrated clinical efficacy?
No. The NASC seal indicates the manufacturer follows Good Manufacturing Practices, maintains accurate labeling, and participates in adverse event reporting. It is a manufacturing quality standard. The NASC seal does not evaluate, verify, or endorse clinical efficacy. A product can carry the seal while containing ingredients with no controlled canine trial evidence of anxiolytic effects.
Why does CBD's demonstrated mechanism in other contexts not confirm anxiolytic effects in dogs?
Mechanism of action plausibility and demonstrated clinical efficacy are different standards. CBD has documented anti-inflammatory and analgesic mechanisms relevant to pain conditions. Behavioral anxiolysis requires demonstrating that the compound changes fear or anxiety endpoints at doses dogs can tolerate — a different outcome from pain modulation. Flint et al. (2025; PMCID: PMC12339541) found that CBD at 2 mg/kg and 4 mg/kg did not significantly attenuate salivary cortisol in a blinded trial specifically designed to test anxiolytic efficacy. Mechanism does not guarantee efficacy for specific outcomes.
Evidence-informed article
Pawsd Knowledge articles are educational and not a substitute for veterinary advice. These pages draw from selected open-access peer-reviewed veterinary research, with full-text sources linked below.
Selected references
Scandurra A, et al. Animals (Basel). 2022;12(4):435. PMCID: PMC8868118. 30-day double-blind placebo-controlled RCT (n=21) of a multi-ingredient botanical-blend calming supplement in dogs.
Flint HE, et al. Front Vet Sci. 2025;12:1632868. PMCID: PMC12339541. Blinded 4-arm crossover (n=54) with salivary cortisol endpoint; CBD monotherapy not significant, combination arm significant.
Sacoor C, et al. Vet Med Int. 2024;2024:2856759. PMCID: PMC10827376. Narrative review of probiotic gut-brain mechanisms; canine behavioral evidence characterized as preliminary.
Riemer S. Animals (Basel). 2023;13(23):3664. PMCID: PMC10705068. Practitioner review including L-theanine evidence for noise-related anxiety.
Benoit S, et al. Nutrients. 2022;14(11):2212. PMCID: PMC9182760. Rodent model confirming alpha-casozepine acts via GABA-A benzodiazepine binding sites.
Related Reading
Acepromazine for Dog Anxiety: Sedation, Fear, and Modern Vet Use
A veterinary-boundary guide to acepromazine for dog anxiety questions, explaining sedation without anxiety relief, noise-fear concerns, historical use, monitoring issues, and modern alternatives.
Dog-Appeasing Pheromone (DAP): Efficacy and Evidence Review
An evidence-based review of dog-appeasing pheromone (DAP) efficacy, vomeronasal processing mechanisms, and clinical limitations in canine behavioral therapy.
Alpha-Casozepine for Dogs: Calming Supplement Evidence and Limits
An evidence-reference guide to alpha-casozepine for dogs, covering proposed GABA-A mechanisms, calming-supplement use, canine evidence limits, combination-product caveats, and when prescription care is more appropriate.
The First Week After Adopting a Dog: Physiological and Behavioral Adjustment
Shelter dogs arrive with elevated physiological stress markers that require time to down-regulate. This guide examines what the research shows about the adjustment arc in newly adopted dogs: the physiological baseline at adoption, the 3-3-3 framework for behavioral adjustment, how schedule predictability reduces arousal, the case for introducing alone time early, and what adopter expectation surveys document about the gap between expected and experienced outcomes.
© 2026 Pawsd LLC. All rights reserved. The selection, arrangement, and original commentary in this guide are the copyrighted work of Pawsd. While the underlying research is publicly available, the editorial analysis, evidence curation, and breed-specific guidance reflect original work. Reproduction or redistribution of this material without written permission is prohibited. For licensing inquiries, contact hello@pawsd.ai.